Study of VIR-5500 for advanced prostate cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests VIR-5500 (AMX-500), a new targeted treatment, in men with prostate cancer that has spread and stopped responding to standard therapies. The goal is to see if it is safe and if it may help shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your prostate cancer has spread to other parts of the body (based on scans like CT, MRI, or bone scan).
- Your cancer is growing despite past treatments, shown by rising PSA or new spots on scans.
- You have already tried at least one newer hormone therapy (like abiraterone, enzalutamide) and one type of chemotherapy (like docetaxel).
- Your cancer is castration-resistant (still growing even when testosterone is very low).
- You are not able to receive or have already tried standard care options for your cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
This trial tests a new type of immune cell therapy (called AB-3028) designed to recognize and attack prostate cancer cells that have the PSMA protein on their surface. It's for people whose prostate cancer has spread and is no longer controlled by hormone therapy.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
This trial tests a combination of two experimental drugs, HS-20093 and HRS-5041, for men with advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to see if this new treatment can help control the cancer when other treatments have stopped working.
This trial tests a new drug called INR731, given by mouth, for men with prostate cancer that has spread to other parts of the body. The study will check if the drug is safe and how well it works, either alone or combined with other prostate cancer medicines.
This study looks back at the experiences of men with prostate cancer that has spread to other parts of the body. It aims to learn which treatments—such as hormone therapy combined with other drugs, or a radioactive therapy—work best for different types of advanced prostate cancer.
Hear when a new Hormone-refractory Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.